Spring Bank Pharmaceuticals, Inc. announced it has appointed Scott Smith as Chairman of the Board, effective January 1, 2019. Mr. Smith will replace Martin Driscoll, Spring Bank’s President and Chief Executive Officer, as Chairman of the Board. Mr. Driscoll will continue to serve as a member of the Board and as President and Chief Executive Officer of the company. Under his leadership as Chairman, Spring Bank has become a publicly traded, clinical-stage company with sufficient capital to fund the company through major clinical data readouts for multiple product candidates. Based on the company’s progress to date, now is an opportune time to separate the roles of Chairman and CEO to enhance the governance for shareholders and the strategic leadership of the company as it progresses forward with multiple opportunities. In addition to the elevation of Mr. Smith to the role of Chairman, Dr. Christiana Bardon has resigned as a member of the Board.